Article Text

Download PDFPDF
What measures are needed to achieve a tobacco endgame target? A Singapore-based simulation study
  1. Zitong Zeng,
  2. Alex R Cook,
  3. Yvette van der Eijk
  1. Saw Swee Hock School of Public Health, National University of Singapore, Singapore
  1. Correspondence to Dr Yvette van der Eijk, Saw Swee Hock School of Public Health, National University of Singapore, Singapore 117549, Singapore; yvette.eijk{at}nus.edu.sg

Abstract

Background An increasing number of countries are pursuing a tobacco ‘endgame’. We sought to determine the combination of measures it would take to achieve a tobacco endgame in the city-state of Singapore.

Methods Using an open-cohort microsimulation model, we estimated the impact of existing measures (quit programmes, tobacco taxes, flavours ban) and more novel measures (very low nicotine cap, tobacco-free generation, raising the minimum legal age to 25 years), and combinations thereof, on smoking prevalence in Singapore over a 50-year horizon. We used Markov Chain Monte Carlo to estimate transition probabilities between the states of never smoker, current smoker and former smoker, updating each individual’s state across each year with prior distributions derived from national survey data.

Results Without new measures, smoking prevalence is expected to rebound from 12.2% (2020) to 14.8% (2070). The only scenarios to achieve a tobacco endgame target within a decade are those combining a very low nicotine cap with a flavours ban. A nicotine cap or tobacco-free generation alone also achieve endgame targets, but after 20 and 39 years, respectively. Taxes, quit programmes, a flavours ban and minimum legal age increase do augment the impact of other measures, but even when combined are insufficient to achieve a tobacco endgame target within 50 years.

Conclusion In Singapore, achieving a tobacco endgame within a decade requires a very low nicotine cap coupled with a tobacco flavours ban, although this target can also be achieved in the long term (within 50 years) with a tobacco-free generation.

  • end game
  • global health
  • prevention
  • public policy

Data availability statement

Data are available in a public, open access repository. Data may be obtained from a third party and are not publicly available. No data are available. A mixture of data sources was used to build the microsimulation model. Some of these are publicly available (eg, national smoking prevalence statistics); others are not publicly available but may be available on request from a third party (eg, Ministry of Health); others are not available due to ethics reasons (eg, survey of flavoured cigarette use).

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Data availability statement

Data are available in a public, open access repository. Data may be obtained from a third party and are not publicly available. No data are available. A mixture of data sources was used to build the microsimulation model. Some of these are publicly available (eg, national smoking prevalence statistics); others are not publicly available but may be available on request from a third party (eg, Ministry of Health); others are not available due to ethics reasons (eg, survey of flavoured cigarette use).

View Full Text

Footnotes

  • Contributors ZZ: data analysis, writing. ARC: conceptualisation, data analysis. YvdE: conceptualisation, data analysis, writing. All authors reviewed and approved the final draft before submission. YvdE is responsible for the overall content as the guarantor, accepts full responsibility for the work and/or conduct of the study, had access to the data, and controlled the decision to publish.

  • Funding This work was supported by funding from the Singapore Health Promotion Board, and Singapore Ministry of Health through the Population Health Metrics and Analytics Programme.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.